Interestingly, EZH2 was also found to support NF-κB target gene expression in triple-negative breast cancer cells by acting as a coactivator in a complex containing RelA and RelB (Figure 3) [95]. The gene discussed is RELB; the disease is triple-negative breast carcinoma.